Trivago Chief Financial Officer Axel Hefer will replace co-founder and CEO Rolf Schrömgens at the end of the year, the company announced.
Hefer told Cheddar in an interview Tuesday the company had been working on a succession plan since he joined the company three years ago.
Schrömgens's co-founders Peter Vinnemeier and Stephan Stubner left the company in 2018. Hefer told Cheddar Schrömgens felt it was time for him "to move into a more passive role." Schrömgens will join the advisory board and give up his board of directors seat.
Trivago's stock was down about 19 percent after the surprising announcement, made along with the Q3 earnings report.
"Our third quarter overall came in softer than expected," he said. The company expects a smaller Q4 revenue than last year.
Hefer said the stock price reaction "is a combination of both filings and, obviously, very difficult to say which part of the drop is associated to the different news."
Hefer said the company has been focused on profitability after losing a "substantial sums of money" in the first half of 2018.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.
